

Stanford Cancer Institute

# Cancer Cell Therapy









Version Date:  
May 6, 2021

## Acute Myeloid Leukemia

Replased/Refractory

**CCT5053**  
Phase I  
KITE-222  
AutologousAnti-CLL-1  
CAR T-Cell  
Therapy in  
Relapsed/  
Refractory Acute  
Myeloid  
Leukemia  
  
PI: Muffly  
Sponsor: Pending

### KEY

- |   |  |   |
|---|--|---|
|  Pending             |  Optional Path                      |  Extension Study |
|  Open for Enrollment |  <a href="#">Link</a> Trial Posting |  Immunotherapy   |
|  Observational Study |  Enrollment on Hold                 |   |